Detection and typing of minimal human papillomavirus DNA in plasma

Wei, Yu-Chi; Chou, Yu-Shen; Chu, Tang-Yuan

doi:10.1016/j.ijgo.2006.08.012

Cited by 32 publications

(40 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HPV-16 and HPV-18 types of HPV are present in approximately 70% of primary tumors [183][184][185]. In contrast to NPC, the potential application of serum / plasma HPV DNA in cervical cancer has not been investigated systematically.…”

Section: Viral Dna In the Circulationmentioning

confidence: 99%

“…Yang et al by means of quantitative PCR have found the incidence of plasma HPV-16/HPV-18 increased to 64.3% in the cases positive for HPV in their primary tumors [184]. The sensitivity of HPV DNA assay was shown to be increased using nested PCR method, which detected a broad spectrum of at least ten genital types of HPV with a sensitivity of one viral copy [183]. HPV DNA was detectable in 65% of the patient plasma, from which the genotype was successfully determined in 9 cases, all identical to that of primary cancer tissue.…”

Section: Viral Dna In the Circulationmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.

show abstract

Section: Viral Dna In the Circulationmentioning

confidence: 99%

Section: Viral Dna In the Circulationmentioning

confidence: 99%

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

show abstract

“…Prior studies of circulating HPV DNA in cervical cancers have reported a pre-treatment detection rate ranging from 12% to 65% and the positivity rate is highly dependent on the patient population and the assay. (19-23) Only one study has evaluated circulating HPV DNA in HNSCC, using a combination of conventional PCR, southern blot hybridization and quantitative PCR (qPCR). (24) In this study, Capone et al were able to detect E6/7 HPV DNA in 6 of 13 patients (46%) with HPV16(+) tumor.…”

Section: Introductionmentioning

confidence: 99%

Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients

Cao

Banh

Kwok

et al. 2012

International Journal of Radiation Oncology*Biology*Physics

112

135

View full text Add to dashboard Cite

Purpose To determine whether HPV DNA can be detected in the plasma of patients with HPV(+) oropharyngeal carcinoma (OP) and to monitor its temporal change during radiotherapy (RT). Methods and Materials We used PCR to detect HPV DNA in the culture media of HPV(+) SCC90, VU147T and the plasma of SCC90 and HeLa tumor bearing mice, non-tumor controls and those bearing HPV(-) tumors. We used real time quantitative PCR (qPCR) to quantify plasma HPV DNA in 40 HPV(+) OP, 24 HPV(-) head and neck cancer (HNC) patients and 10 non-cancer volunteers. Tumor HPV status was confirmed by p16INK4a staining and HPV16/18 PCR or HPV ISH. 14 patients had serial plasma samples for HPV DNA quantification during RT. Results HPV DNA was detectable in the plasma samples of SCC90- and HeLa-bearing mice but not in controls. It was detected in 65% of pretreatment plasma samples from HPV(+) OP patients using E6/7 qPCR. None of the HPV(-) HNC or non-cancer controls had detectable HPV DNA. Pretreatment plasma HPV DNA copy number correlated significantly with nodal metabolic tumor volume (assessed on FDG-PET). Serial measurements in 14 patients showed rapid decline in HPV DNA that became undetectable at RT completion. In 3 patients, HPV DNA rose to discernable level at the time of metastasis. Conclusions Xenograft studies indicated that plasma HPV DNA is released from HPV(+) tumors. Circulating HPV DNA is detectable in most HPV(+) OP patients. Plasma HPV DNA may be a valuable tool for identifying relapse.

show abstract

“…There aren't any reports as how the virus is able to infect other organs; two mechanisms though, have been proposed: a mechanical path where the virus is scrubbed through the skin [25], and a systemic path where HPV spreads through the bloodstream by organ perfusion [36]. Whether any or both mechanisms are responsible for HPV propagation is not clear, HPV DNA has been found in plasma of patients with diagnosis of cervical cancer [37][38][39][40], and in sera of patients with breast cancer [24] and with HPV-associated head and neck squamous cell carcinoma [41]. Another reason for the few positive detected is the differential selective advantage given to the neoplastic cells by HPV and the relative number of infected cells within the clone pool.…”

Section: Discussionmentioning

confidence: 99%

Low frequency of human papillomavirus DNA in breast cancer tissue

Mendizabal-Ruiz

Morales

Ramírez-Jirano

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Human papillomavirus (HPV) is considered the aetiological agent for cervical cancer. Several reports have addressed a relationship with HPV and breast cancer, as different HPVs have been identified. The purpose of this study was to detect HPV DNA in 67 breast cancer patients and 40 non-malignant disease breast tissues by means of Polymerase Chain Reaction with consensus primers. The frequency of HPV in the cases group were 4.4% (3/67) and no positive samples among the reference group were identified. From the 3 positive samples, HPV types 16, 18 and 33 were identified by restriction patterns and direct sequencing. The high diversity among detection in the related studies shows that population genomic heterogeneity plays an important role in the disease. The low frequency detected in the present study suggests that HPV does not play an important role in breast cancer.

show abstract

Detection and typing of minimal human papillomavirus DNA in plasma

Abstract: The high sensitivity and accuracy of this method has allowed detection of HPV in specimens of minimal viral load, such as in plasma in peripheral circulation of cervical cancer patients.

Cited by 32 publications

References 17 publications

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients

Low frequency of human papillomavirus DNA in breast cancer tissue

Contact Info

Product

Resources

About